Trinity Biotech plc acquires, develops, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of th…
$5.70-3.31%
报价 2026-11-06
市值
$115.4M
EV
$293.4M
PE (TTM)
–
预期 PE
–
52 周区间距高点 -85.2%
$5.69$38.40
筛选结果
pipeline · 2026-11-06Filter✗ 高增长✗ Cheap✗ GARP
market cap below $300M floor
研究结论
还没有研究记录。先生成 L2 基本面报告（约 1–3 分钟），结论会显示在这里。
去生成基本面报告 →历史股价
加载中…
事件
0 条 · 随区间与图例筛选该区间内无事件。
同行对比
同行业市值相近 · Medical - Diagnostics & Research| 公司 | 市值 | 今日 | 预期营收增速 | 毛利率 | PE | EV/EBITDA | P/FCF | 池 |
|---|---|---|---|---|---|---|---|---|
| TRIBTrinity Biotech plc | $115.4M | -3.3% | – | 38.5% | – | – | – | |
| MYGNMyriad Genetics, Inc. | $566.2M | -5.9% | +5.1% | 68.8% | – | – | – | |
| PREPrenetics Global Limited | $270M | -1.1% | – | 62.6% | – | – | – | |
| STIMNeuronetics, Inc. | $163.8M | -11.5% | +8.8% | 50.7% | – | – | – | |
| XGNExagen Inc. | $140.7M | -23.6% | +7.7% | 58.6% | – | – | – | |
| SERASera Prognostics, Inc. | $84.3M | +5.3% | +300.0% | -191.2% | – | – | – | |
| BDSXBiodesix, Inc. | $69.4M | -57.0% | +29.1% | 82.5% | – | – | – | |
| STRRStar Equity Holdings, Inc. | $33.6M | -4.0% | +35.4% | 43% | – | – | – | |
| PRPOPrecipio, Inc. | $33.3M | +0.2% | +23.7% | 43.7% | – | 203.0x | 63.0x | |
| 同行中位数 | – | – | +23.7% | 54.7% | – | 203.0x | 63.0x |
研究全文
L2 基本面 memo
尚无基本面 memo
点击「生成基本面报告」——基于最新 filings、电话会纪要与分析师共识生成 L2 memo。
财务报表
暂无季度数据（首次研究运行后填充）。
研究材料
Filing 摘要
电话会纪要摘要
暂无纪要摘要。